Sirolimus is under clinical development by Palvella Therapeutics and currently in Phase III for Lymphoproliferative Disorders. According to GlobalData, Phase III drugs for Lymphoproliferative Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Sirolimus LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sirolimus overview
Sirolimus (Rapatane) is under development for the treatment of microcystic lymphatic malformation (lymphoproliferative disorders), cutaneous venous malformation and Gorlin syndrome. The drug candidate is administered through the topical route. The drug candidate acts by targeting mTOR.
It was under development for the treatment of pachyonychia congenita and epidermolysis bullosa.
Palvella Therapeutics overview
Palvella Therapeutics Inc (Palvella Therapeutics) is a clinical-stage biopharmaceutical company. It develops and commercializes novel therapies to treat patients suffering from serious, rare genetic skin diseases. The company offers QTORIN which is a patented and versatile platform designed to deliver APIs to deep layers of the skin to locally treat a broad spectrum of rare skin diseases. Its pipeline product include QTORIN rapamycin which treats microcystic lymphatic malformations, venous malformations and other mTOR-driven skin diseases. Palvella Therapeutics is headquartered in Wayne, Pennsylvania, the US.
For a complete picture of Sirolimus’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
